JUNSHI BIO (01877) announces the publication of phase 2 study data for anti-PD-1 monoclonal antibody in nasopharyngeal cancer, showing an objective response rate of 61.9% in patients.

On November 6th, JUNSHI BIO (01877) announced that the latest data from a phase 2 study on the combination of Toripalimab and Gemcitabine as first-line treatment for cisplatin-intolerant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) has been published in the international journal Cell Reports Medicine. The study results showed an objective response rate (ORR) of 61.9%, a disease control rate (DCR) of 100%, a median progression-free survival (PFS) of 11.8 months, and significantly lower toxicity compared to standard platinum-containing treatment, with only 23.8% of patients experiencing grade 3 adverse events (AE). JUNSHI BIO's press release stated that this treatment regimen has optimized and upgraded efficacy and safety for cisplatin-intolerant R/M NPC patients. The combination of Toripalimab, a PD-1 inhibitor, with Gemcitabine and cisplatin (GP) has become the standard first-line treatment for R/M NPC patients. However, cisplatin has significant toxicity, and some patients may not tolerate cisplatin treatment due to renal impairment, poor physical condition, hearing loss, or heart failure. Toripalimab has been approved for the treatment of R/M NPC in China, the United States, and the European Union. Considering its long-term efficacy and low toxicity profile, this study hypothesized that the combination of Toripalimab with the less toxic chemotherapy drug Gemcitabine could improve safety without compromising efficacy, ultimately achieving a platinum-sparing goal.